Aranesp 30 micrograms solution for injection in pre-filled syringe

Patient Information Leaflet

Introduction

Patient Information Leaflet

Aranesp 10 micrograms solution for injection in pre-filled syringe

Aranesp 15 micrograms solution for injection in pre-filled syringe

Aranesp 20 micrograms solution for injection in pre-filled syringe

Aranesp 30 micrograms solution for injection in pre-filled syringe

Aranesp 40 micrograms solution for injection in pre-filled syringe

Aranesp 50 micrograms solution for injection in pre-filled syringe

Aranesp 60 micrograms solution for injection in pre-filled syringe

Aranesp 80 micrograms solution for injection in pre-filled syringe

Aranesp 100 micrograms solution for injection in pre-filled syringe

Aranesp 130 micrograms solution for injection in pre-filled syringe

Aranesp 150 micrograms solution for injection in pre-filled syringe

Aranesp 300 micrograms solution for injection in pre-filled syringe

Aranesp 500 micrograms solution for injection in pre-filled syringe

darbepoetin alfa (darbepoetin alfa)

Read the entire leaflet carefully before you start using this medicine, because it contains important information for you.

• Keep this leaflet as you may need to read it again.
• If you have any questions, ask your doctor, pharmacist, or nurse.
• This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, because it could harm them.
• If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if they are effects not listed in this leaflet. See section 4.

Leaflet Contents

1. What Aranesp is and what it is used for
2. What you need to know before using Aranesp
3. How to use Aranesp
4. Possible side effects
5. How to store Aranesp
6. Contents of the pack and other information

1. What Aranesp is and what it is used for

Your doctor has prescribed you Aranesp (an anti-anaemic agent) to treat your anaemia. Anaemia occurs when the blood does not contain enough red blood cells, and symptoms may include fatigue, weakness, and shortness of breath.

Aranesp works in exactly the same way as the natural hormone erythropoietin. Erythropoietin is produced in the kidneys and helps the bone marrow produce more red blood cells. The active substance in Aranesp is darbepoetin alfa, produced by genetic technology in Chinese Hamster Ovary cells (CHO-K1).

If you have chronic renal failure

Aranesp is used to treat symptomatic anaemia associated with chronic renal failure (kidney failure) in adults and children. In kidney failure, the kidneys do not produce enough of the natural hormone erythropoietin, which often leads to anaemia.

Since your body will need some time to produce more red blood cells, it will take about four weeks before you notice any effect. Your regular dialysis routine will not affect Aranesp's ability to treat anaemia.

If you are receiving chemotherapy

Aranesp is used to treat symptomatic anaemia in adult patients with non-myeloid tumours who are being treated with chemotherapy.

One of the main side effects of chemotherapy is that it causes the bone marrow to stop producing enough red blood cells. Towards the end of chemotherapy treatment, especially if you have received a lot of chemotherapy, your red blood cell count may drop, causing anaemia.

2. What you need to know before using Aranesp

Do not use Aranesp:

• if you are allergic to darbepoetin alfa or to any of the other components of this medicine (listed in section 6);
• if you have high blood pressure that is not being treated with other medicines prescribed by your doctor.

Warnings and precautions

Talk to your doctor, pharmacist, or nurse before starting to use Aranesp.

Inform your doctor if you have or have had:

• high blood pressure being treated with medicines prescribed by your doctor;
• sickle cell anemia;
• epileptic seizures (fits);
• convulsions (spasms and seizures);
• liver disease;
• no response to medications used to treat anemia;
• latex allergy (the needle cap of the pre-filled syringe contains a latex derivative); or
• hepatitis C.

Special precautions:

• If you experience symptoms such as unusual tiredness and lack of energy, this may be due to a disorder called pure red cell aplasia (PRCA), which has been observed in some patients. PRCA means that your body has reduced or stopped producing red blood cells, leading to severe anemia. If you experience these symptoms, contact your doctor, who will determine the best way to treat your anemia.

• Exercise special caution with other medicines that stimulate red blood cell production: Aranesp belongs to a group of medicines that stimulate red blood cell production, similar to human erythropoietic proteins. Your doctor should always keep a record of the exact medicine you are using.

• If you are a patient with chronic renal failure and especially if you do not respond properly to Aranesp, your doctor will review the Aranesp dose, because if you do not respond to treatment, repeated dose increases of Aranesp could increase the risk of heart or blood vessel problems and could increase the risk of myocardial infarction, stroke, and death.

• Your doctor will aim to keep your hemoglobin levels between 10 and 12 g/dL. Your doctor will monitor to ensure your hemoglobin does not exceed a certain level, as high hemoglobin concentrations may put you at risk of heart or blood vessel problems and could increase the risk of myocardial infarction, stroke, and death.

• If you experience symptoms such as severe headache, numbness, confusion, vision problems, nausea, vomiting, or seizures (convulsions), this may indicate very high blood pressure. If you experience these symptoms, contact your doctor immediately.

• If you are a cancer patient, you should know that Aranesp can act as a growth factor for blood cells and, under certain circumstances, may have a negative effect on your cancer. Depending on your individual situation, a blood transfusion may be preferable. Please discuss this with your doctor.

• The use of this medicine in healthy individuals may cause heart or blood vessel problems that could be fatal.

• Cases of serious skin reactions associated with epoetin therapy have been reported, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). SJS/TEN may initially appear as red, target-like spots or circular rashes, often with central blisters, on the torso. In addition, mouth ulcers may occur in the mouth, throat, nose, genitals, and eyes (red and swollen eyes). These severe rashes are often preceded by fever or flu-like symptoms. The rashes may progress to widespread skin peeling and potentially life-threatening complications. If you develop a severe rash or any of these skin symptoms, stop taking Aranesp and contact your doctor or seek immediate medical attention.

Using Aranesp with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Cyclosporine and tacrolimus (medicines that suppress the immune system) may be affected by the number of red blood cells. It is important to inform your doctor if you are taking any of these medicines.

Using Aranesp with food and drink

Food and drink do not affect Aranesp.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

Aranesp has not been used in pregnant women. It is important to inform your doctor if you:

• are pregnant;
• think you may be pregnant; or
• plan to become pregnant.

It is unknown whether darbepoetin alfa is excreted in human milk. If you are being treated with Aranesp, you should discontinue breastfeeding.

Driving and using machines

Aranesp should not affect your ability to drive or operate machinery.

Aranesp contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose, i.e., essentially "sodium-free".

3. How to use Aranesp

Follow exactly the administration instructions for this medicine given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

After blood tests, your doctor has decided that you need Aranesp because your hemoglobin level is equal to or less than 10 g/dL. Your doctor will tell you how much Aranesp you need and how often you should use it to keep your hemoglobin level between 10 and 12 g/dL. This may vary depending on whether you are an adult or a child.

How to self-inject Aranesp

Your doctor may decide it is best for you or your caregivers to inject Aranesp yourself. Your doctor, nurse, or pharmacist will teach you how to administer the injection using the pre-filled syringe. Do not attempt to self-inject if you have not been trained. Never inject Aranesp into a vein yourself.

If you have chronic renal failure

For all adult and pediatric patients ≥ 1 year of age with chronic renal failure, Aranesp is administered as a single injection either under the skin (subcutaneously) or into a vein (intravenously).

To correct anemia, the initial dose of Aranesp per kilogram of body weight will be:

• 0.75 micrograms once every two weeks, or
• 0.45 micrograms once weekly.

For adult patients not undergoing dialysis, 1.5 micrograms/kg once monthly may also be used as the initial dose.

For all adult and pediatric patients ≥ 1 year of age with chronic renal failure, once your anemia is corrected, you will continue receiving Aranesp as a single injection either once weekly or once every two weeks. For all adult and pediatric patients ≥ 11 years of age who are not on dialysis, Aranesp may also be administered as a monthly injection.

Your doctor will perform regular blood tests to monitor how your anemia is responding to treatment and, if necessary, may adjust your dose every four weeks to maintain long-term control of your anemia.

Your doctor will use the lowest effective dose to control your anemia symptoms.

If you do not respond adequately to Aranesp, your doctor will review your dose and inform you if a dose adjustment is needed.

Your doctor will measure your blood pressure regularly, especially at the beginning of treatment.

In some cases, your doctor may recommend taking iron supplements.

Your doctor may decide to change the route of administration (subcutaneous or intravenous). If this occurs, you will start with the same dose you were previously receiving, and blood tests will be performed to ensure your anemia continues to be properly treated.

If your doctor has decided to switch your treatment from r-HuEPO (recombinant human erythropoietin) to Aranesp, they will choose between administering Aranesp once weekly or once every two weeks. The route of administration will be the same as with r-HuEPO, but your doctor will determine the dose and timing, and may adjust your dose as necessary.

If you are receiving chemotherapy

Aranesp is administered subcutaneously as a single injection once weekly or once every three weeks.

To correct your anemia, the initial dose of Aranesp will be:

• 500 micrograms once every three weeks (6.75 micrograms of Aranesp per kilogram of body weight), or
• 2.25 micrograms of Aranesp per kilogram of body weight (once weekly).

Your doctor will regularly take blood samples to monitor your response to treatment and may adjust the dose as needed. Treatment will continue until approximately 4 weeks after the end of chemotherapy. Your doctor will tell you exactly when to stop taking Aranesp.

In some cases, your doctor may recommend taking iron supplements.

If you use more Aranesp than you should

You may experience serious problems if you administer more Aranesp than you should, such as very high blood pressure. Contact your doctor or pharmacist if this happens. If you feel unwell, contact your doctor or pharmacist immediately.

If you forget to use Aranesp

Do not take a double dose to make up for a missed dose.

If you forget to inject a dose of Aranesp, contact your doctor to determine when you should inject the next dose.

If you stop using Aranesp

If you wish to stop using Aranesp, you must first discuss this with your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been reported in some patients using Aranesp:

Patients with chronic renal failure

Very common: may affect more than 1 in 10 people

• High blood pressure (hypertension)
• Allergic reactions

Common: may affect up to 1 in 10 people

• Stroke
• Pain at the injection site
• Skin rash and/or redness

Uncommon: may affect up to 1 in 100 people

• Blood clots (thrombosis)
• Seizures (spasms and fits)

Frequency not known: frequency cannot be estimated from the available data

• Pure red cell aplasia (PRCA) – (anemia, unusual tiredness, lack of energy)

Patients with cancer

Very common: may affect more than 1 in 10 people

• Allergic reactions
• Fluid retention (edema)

Common: may affect up to 1 in 10 people

• High blood pressure (hypertension)
• Blood clots (thrombosis)
• Pain at the injection site
• Skin rash and/or redness

Uncommon: may affect up to 1 in 100 people

• Seizures (spasms and fits)

All patients

Frequency not known: frequency cannot be estimated from the available data

• Severe allergic reactions which may include:

• Unexpected allergic reactions that may be life-threatening (anaphylaxis)

• Swelling of the face, lips, mouth, tongue, or throat which may cause difficulty in swallowing or breathing (angioedema)

• Difficulty breathing (allergic bronchospasm)

• Skin rashes

• Rash (urticaria)

• Severe skin reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with epoetin therapy. These may appear as reddish, target-like spots or circular patches, often with central blisters on the trunk, peeling of the skin, mouth, throat, nose, genital, and eye sores, and may be preceded by fever or flu-like symptoms.

Stop taking Aranesp and contact your doctor or seek immediate medical attention if you experience any of these symptoms. See also section 2.

• Bruising and bleeding at the injection site

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse, including any possible side effects not listed in this leaflet. You can also report them directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Aranesp

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton and label after "CAD" or "EXP". The expiry date refers to the last day of the month indicated.

Store in a refrigerator (between 2°C and 8°C). Do not freeze. Do not use Aranesp if you think it has been frozen.

Keep the pre-filled syringe in the outer carton to protect it from light.

Once you have removed your syringe from the refrigerator and allowed it to reach room temperature for approximately 30 minutes prior to injection, it must be used within the following 7 days or discarded.

Do not use this medicine if you notice that the solution in the syringe is cloudy or contains particles.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Aranesp

• The active substance is darbepoetin alfa, r-HuEPO (erythropoietin produced by recombinant DNA technology). The pre-filled syringes contain 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 300 or 500 micrograms of darbepoetin alfa.
• The other components are monobasic sodium phosphate, dibasic sodium phosphate, sodium chloride, polysorbate 80 and water for injections.

Appearance of the product and contents of the pack

Aranesp is a clear, colourless or slightly opalescent injectable solution in a pre-filled syringe.

Aranesp is available in packs containing 1 or 4 pre-filled syringes with an automatic needle protection device, packed in blisters. Only certain pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Amgen Europe B.V.

Minervum 7061

NL-4817 ZK Breda

The Netherlands

Marketing Authorization Holder

Amgen Europe B.V.

Minervum 7061

NL-4817 ZK Breda

The Netherlands

Manufacturer

Amgen Technology (Ireland) Unlimited Company

Pottery Road

Dun Laoghaire

Co Dublin

Ireland

Manufacturer

Amgen NV

Telecomlaan 5-7

1831 Diegem

Belgium

Further information on this medicinal product is available upon request by contacting the local representative of the Marketing Authorization Holder.

Belgium/Belgium/Belgium s.a. Amgen n.v. Tel/Tel: +32 (0)2 7752711	Lithuania Amgen Switzerland AG Vilnius Branch Tel: +370 5 219 7474
	Luxembourg/Luxembourg s.a. Amgen Belgium/Belgium Tel/Tel: +32 (0)2 7752711
Czech Republic Amgen s.r.o. Tel: +420 221 773 500	Hungary Amgen Kft. Tel.: +36 1 35 44 700
Denmark Amgen, branch of Amgen AB, Sweden Tlf: +45 39617500	Malta Amgen B.V. The Netherlands Tel: +31 (0)76 5732500
Germany AMGEN GmbH Tel.: +49 89 1490960	Netherlands Amgen B.V. Tel: +31 (0)76 5732500
Estonia Amgen Switzerland AG Vilnius Branch Tel: +372 586 09553	Norway Amgen AB Tel: +47 23308000
Greece Amgen Hellas Pharmaceutical E.P.E. Tel.: +30 210 3447000	Austria Amgen GmbH Tel: +43 (0)1 50 217
Spain Amgen S.A. Tel: +34 93 600 18 60	Poland Amgen Biotechnologia Sp. z o.o. Tel.: +48 22 581 3000
France Amgen S.A.S. Tel: +33 (0)9 69 363 363	Portugal Amgen Biofarmacêutica, Lda. Tel: +351 21 4220550
Croatia Amgen d.o.o. Tel: +385 (0)1 562 57 20	Romania Amgen România SRL Tel: +4021 527 3000
Ireland Amgen Limited United Kingdom Tel: +44 (0)1223 420305	Slovenia AMGEN zdravila d.o.o. Tel: +386 (0)1 585 1767
Iceland Vistor hf. Tel: +354 535 7000	Slovakia Amgen Slovakia s.r.o. Tel: +421 2 321 114 49
Italy Amgen S.r.l. Tel: +39 02 6241121	Finland/Finland Amgen AB, branch in Finland/Amgen AB, filial i Finland Puh/Tel: +358 (0)9 54900500
Cyprus C.A. Papaellinas Ltd Tel.: +357 22741 741	Sweden Amgen AB Tel: +46 (0)8 6951100
Latvia Amgen Switzerland AG Riga Branch Tel: +371 257 25888	United Kingdom Amgen Limited Tel: +44 (0)1223 420305

Date of the most recent review of this leaflet:

Other sources of information

Detailed information on this medicine is available on the website of the European Medicines Agency: http://www.ema.europa.eu.

This leaflet is available in all EU/EEA languages on the website of the European Medicines Agency.